Best Stocks Under $1.00 for 2018

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Genocea Biosciences (NASDAQ:GNCA)

Stock Price: $0.61
Market Cap: $51.11 million
P/E Ratio: -0.3
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.7857 (684.5% Upside)

Genocea Biosciences logoGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
#2 - Catabasis Pharmaceuticals (NASDAQ:CATB)

Stock Price: $0.65
Market Cap: $19.51 million
P/E Ratio: -0.5
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.9167 (656.4% Upside)

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.
#3 - Golden Star Resources (NYSEAMERICAN:GSS)

Stock Price: $0.74
Market Cap: $362.27 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $0.9750 (31.8% Upside)

Golden Star Resources logoGolden Star Resources Ltd. operates as a gold mining and exploration company. The company owns and operates the Wassa open-pit gold mine, the Wassa underground mine, and a carbon-in-leach processing plant located to the northeast of the town of Tarkwa, Ghana; and Bogoso gold mining and processing operation, Prestea open-pit mining operations, and the Prestea underground development project located near the town of Prestea, Ghana. It also holds and manages interests in various gold exploration properties in Ghana and Brazil. The company was incorporated in 1992 and is headquartered in Toronto, Canada.
#4 - Eco-Stim Energy Solutions (NASDAQ:ESES)

Stock Price: $0.60
Market Cap: $42.30 million
P/E Ratio: -2.3
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.3750 (295.8% Upside)

Eco-Stim Energy Solutions logoEco-Stim Energy Solutions, Inc. provides oilfield services in the United States and Argentina. The company offers pressure pumping, coiled tubing, and field management services to the upstream oil and gas industry. Its customers consist primarily of international oil and gas exploration and production companies, including national oil companies, local privately-held exploration and production companies, and other service companies. The company is headquartered in Houston, Texas.
#5 - Agile Therapeutics (NASDAQ:AGRX)

Stock Price: $0.27
Market Cap: $8.66 million
P/E Ratio: -0.3
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.25 (2,214.8% Upside)

Agile Therapeutics logoAgile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
#6 - ConforMIS (NASDAQ:CFMS)

Stock Price: $0.93
Market Cap: $61.28 million
P/E Ratio: -0.8
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $3.75 (303.2% Upside)

ConforMIS logoConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
#7 - Rewalk Robotics (NASDAQ:RWLK)

Stock Price: $0.93
Market Cap: $29.10 million
P/E Ratio: -0.9
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.80 (201.1% Upside)

Rewalk Robotics logoReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. It is also developing ReWalk Restore, a soft suit exoskeleton for individuals who have suffered a stroke. ReWalk Robotics Ltd. markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokne'am Illit, Israel.
#8 - Obsidian Energy (NYSE:OBE)

Stock Price: $0.98
Market Cap: $495.05 million
P/E Ratio: -7.3
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.71 (74.5% Upside)

Obsidian Energy logoObsidian Energy Ltd. explores for, develops, and produces oil and natural gas in western Canada. The company primarily holds interests in the Cardium development area that covers an area of approximately 450 net sections of developed and undeveloped land located in west central Alberta; Peace River development area covering an area of 235 net sections of developed and undeveloped land located in northwestern Alberta; and Viking development area that covers an area of approximately 170 net sections of developed and undeveloped land located in Eastern Alberta. It also owns an interest in the Deep Basin development area covering an area of 700 net sections of developed and undeveloped land located located in Alberta. The company was formerly known as Penn West Petroleum Ltd. and changed its name to Obsidian Energy Ltd. in June 2017. Obsidian Energy Ltd. was founded in 1979 and is headquartered in Calgary, Canada.
#9 - Egalet (NASDAQ:EGLT)

Stock Price: $0.30
Market Cap: $20.73 million
P/E Ratio: -0.1
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.00 (900.0% Upside)

Egalet logoEgalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
#10 - Flex Pharma (NASDAQ:FLKS)

Stock Price: $0.59
Market Cap: $11.38 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.50 (2,866.1% Upside)

Flex Pharma logoFlex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis; and two Phase 2 clinical trials in the United States for the treatment of patients with motor neuron disease in amyotrophic lateral sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT product online through its e-commerce Website, as well as through specialty retailers. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
#11 - Celldex Therapeutics (NASDAQ:CLDX)

Stock Price: $0.43
Market Cap: $69.04 million
P/E Ratio: -0.5
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.50 (946.5% Upside)

Celldex Therapeutics logoCelldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
#12 - Teekay Tankers (NYSE:TNK)

Stock Price: $0.98
Market Cap: $273.93 million
P/E Ratio: -8.9
Dividend Yield: 5.88 %
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $1.65 (68.4% Upside)

Teekay Tankers logoTeekay Tankers Ltd. provides marine transportation services to oil industries in Bermuda and internationally. The company operates through two segments, Conventional Tanker and Ship-To-Ship Transfer. It is involved in the marine transportation of crude oil and refined petroleum products through the operation of its oil and product tankers. The company also provides ship-to-ship transfer services, including lightering and lightering support, consultancy, and LNG terminal management services. As of December 31, 2017, it operated a fleet of 52 owned conventional tankers, 4 conventional tankers related to capital leases, 1 in-chartered vessel, and 1 jointly-owned very large crude carrier; and 6 ship-to-ship support vessels. The company's vessels operated under fixed-rate time charter contracts with its customers. Teekay Tankers Ltd. was founded in 2007 and is based in Hamilton, Bermuda.
#13 - GASTAR EXPL INC/SH (NYSEAMERICAN:GST)

Stock Price: $0.10
Market Cap: $151.07 million
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $1.0325 (932.5% Upside)

GASTAR EXPL INC/SH logoGastar Exploration Inc., an independent energy company, engages in the exploration, development and production of oil, condensate, natural gas, and natural gas liquids in the United States. Its principal activities include the identification, acquisition, exploration, and development of oil and natural gas properties on unconventional reserves, such as shale resource plays. The company holds interests in the oil and natural gas-rich reservoirs, including the Oswego limestone, Meramec, and Osage bench formations within the Mississippi Lime; and the Woodford shale formations. As of February 28, 2018, its principal assets included the STACK play covering approximately 67,800 net acres located in the Mid-Continent area of the United States. The company was formerly known as Gastar Exploration Ltd. and changed its name to Gastar Exploration Inc. in January 2014. Gastar Exploration Inc. is based in Houston, Texas.
#14 - Iconix Brand Group (NASDAQ:ICON)

Stock Price: $0.42
Market Cap: $30.80 million
P/E Ratio: 0.5
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.00 (1,090.5% Upside)

Iconix Brand Group logoIconix Brand Group, Inc. is a brand management company. As of December 31, 2016, the Company owned a portfolio of over 30 global consumer brands across women's, men's, and home categories. The Company operates through segments: men's, women's, home and international. The Company's brand portfolio includes brands, such as Candie's, Bongo, Joe Boxer, Rampage, Mudd, London Fog, Mossimo, Ocean Pacific/OP, Danskin/Danskin Now, Rocawear/Roc Nation, Cannon, Royal Velvet, Fieldcrest, Charisma, Starter, Waverly, Ecko Unltd/Mark Ecko Cut & Sew, Zoo York, Umbro, Lee Cooper and Artful Dodger, and interests in Material Girl, Ed Hardy, Truth or Dare, Modern Amusement, Buffalo, Nick Graham Hydraulic and PONY brands. It operates in various geographic regions, including the United States, Japan and Other (which principally represent Latin America and Europe).
#15 - Rex Energy (NASDAQ:REXX)

Stock Price: $0.53
Market Cap: $5.94 million
P/E Ratio: -0.1
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.79 (240.8% Upside)

Rex Energy logoRex Energy Corporation is an independent oil, natural gas liquid (NGL) and natural gas company. The Company has operations in the Appalachian Basin and Illinois Basin. In the Appalachian Basin, the Company is focused on its Marcellus Shale, Utica Shale and Upper Devonian (Burkett) Shale drilling and exploration activities. In the Illinois Basin, the Company is focused on its developmental oil drilling on its properties. The Company owns an interest in approximately 1,820 oil and natural gas wells. The Company produces an average of over 195.8 net millions of cubic feet equivalent (MMcfe) per day, composed of approximately 62.4% natural gas, over 9.5% oil and approximately 28.1% NGLs. In the Illinois Basin, the Company produces an average of approximately 1,998 barrels of oil per day (bopd). Including both developed and undeveloped acreage, the Company controls approximately 99,200 gross (over 79,700 net) acres in Illinois, Indiana and Kentucky.
#16 - Regulus Therapeutics (NASDAQ:RGLS)

Stock Price: $0.26
Market Cap: $22.43 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.10 (323.1% Upside)

Regulus Therapeutics logoRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
#17 - Asanko Gold (NYSEAMERICAN:AKG)

Stock Price: $0.90
Market Cap: $174.19 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.3750 (52.8% Upside)

Asanko Gold logoAsanko Gold Inc. engages in the exploration, development, and production of gold properties. Its principal project is the Asanko Gold Mine, which consists of two gold projects, such as the Obotan Project and the Esaase Project located in the Amansie West District of the Republic of Ghana, West Africa. The company was formerly known as Keegan Resources Inc. and changed its name to Asanko Gold Inc. in February 2013. Asanko Gold Inc. was incorporated in 1999 and is headquartered in Vancouver, Canada.
#18 - Eldorado Gold (NYSE:EGO)

Stock Price: $0.99
Market Cap: $809.89 million
P/E Ratio: 50.0
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 5 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $1.20 (21.2% Upside)

Eldorado Gold logoEldorado Gold Corporation, together with its subsidiaries, engages in the exploration, development, and mining of gold properties in Turkey, Greece, Brazil, Serbia, Canada, and Romania. The company holds 100% interests in the Kisladag and Efemcukuru gold mines in Turkey; Lamaque gold project in Canada; Perama Hill gold-silver project and Sapes in Greece; and Vila Nova iron ore mine and Tocantinzinho gold project in Brazil. It also holds 95% interests in Olympias gold mine, Stratoni silver-lead-zinc mine, and Skouries gold-copper project in Greece; and 80.5% interests in Certej gold-silver project in Romania. The company was formerly known as Eldorado Corporation Ltd. and changed its name to Eldorado Gold Corporation in April 1996. Eldorado Gold Corporation was founded in 1992 and is headquartered in Vancouver, Canada.
#19 - Tintri (NASDAQ:TNTR)

Stock Price: $0.16
Market Cap: $5.53 million
P/E Ratio: 0.0
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 5 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $7.70 (4,580.9% Upside)

Tintri logoTintri, Inc. develops and markets an enterprise cloud platform combining cloud management software technology and a range of all-flash storage systems for virtualized and cloud environments in the United States and internationally. The company's platform provides large organizations and cloud service providers with public cloud capabilities inside their data centers and public cloud services. Its products and technologies include Tintri CONNECT, a proprietary software architecture for virtualized and cloud applications; Tintri OS, which helps the interaction between the virtualized infrastructure and the underlying storage serving that infrastructure; Tintri Global Center, an intelligent data and system management product; and VM Scale-out software, which creates resource pools of Tintri storage systems and optimizes the location of applications. The company's products and technologies also include predictive analytics solutions for customers to model their current and future storage requirements; ReplicateVM, the replication solutions for data protection and disaster recovery; SyncVM, a solution for copy data management; SecureVM, a solution for encryption of data-at-rest; Tintri Cloud Connector, which allows customers to use public cloud storage for storing snapshots; and storage systems, such as EC6000 all-flash systems, T800 hybrid-flash systems, and T1000 all-flash system. It also offers its products related support, installation, and training services. The company serves customer in education, financial services, insurance, healthcare, manufacturing, and automotive technology, as well as cloud service providers. Tintri, Inc. was founded in 2008 and is headquartered in Mountain View, California.
#20 - Jones Energy (NYSE:JONE)

Stock Price: $0.40
Market Cap: $50.73 million
P/E Ratio: -1.0
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $0.8333 (108.3% Upside)

Jones Energy logoJones Energy, Inc., an independent oil and gas company, engages in the acquisition, exploration, development, and production of oil and natural gas properties in the mid-continent United States. It owns leasehold interests in oil and natural gas producing properties, as well as in undeveloped acreage located in the Anadarko Basin in Oklahoma and Texas. As of December 31, 2017, the company's total estimated proved reserves included 104.8 million barrels of oil equivalent. Jones Energy, Inc. was founded in 1988 and is headquartered in Austin, Texas.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.